Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21294969 | 0.93 | SCN9A (0.40) | SCN9AMEN1KMT2APOLBHPGD | |
| SCHEMBL15465196 | 0.91 | POLB (0.41) | SCN9AMEN1KMT2APOLBHPGD | |
| SCHEMBL15465137 | 0.90 | SCN9A (0.40) | SCN9AMEN1KMT2APOLBHPGD | |
| SCHEMBL15466190 | 0.88 | GAA (0.41) | SCN9AMEN1KMT2APOLBHPGD | |
| SCHEMBL29668966 | 0.88 | GAA (0.41) | SCN9AMEN1KMT2APOLBHPGD | |
| SCHEMBL15464432 | 0.88 | POLB (0.39) | SCN9AMEN1KMT2APOLBTP53 | |
| SCHEMBL21294704 | 0.88 | POLB (0.40) | SCN9AMEN1KMT2APOLBHPGD | |
| SCHEMBL15465532 | 0.88 | SCN9A (0.42) | SCN9AMEN1KMT2APOLBHPGD | |
| SCHEMBL18843942 | 0.88 | CNR2 (0.47) | MEN1KMT2APOLBHPGDCNR2 | |
| SCHEMBL25090156 | 0.85 | POLB (0.40) | MEN1KMT2APOLBHPGDCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2974730-B1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO CO LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-3144300-B1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | DAIICHI SANKYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| EP-3144300-A1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | Daiichi Sankyo Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-9597330-B2 | Drugs for treating respiratory diseases | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9493448-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-2813491-B1 | CYCLOALKANE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20160038486-A1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2974730-A1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2813491-A1 | CYCLOALKANE DERIVATIVE | Daiichi Sankyo Co., Ltd. (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8889741-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20140045862-A1 | Cycloalkane Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038486-A1 | DRUG FOR RESPIRATORY DISEASES | SCN1B, NHERF1, SCNN1A | SCN9A 194/4885MEN1 2014/4885KMT2A 4408/4885 |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | TRPV1, TRPA1, SCNN1A | SCN9A 64/4885MEN1 3769/4885KMT2A 4560/4885 |
| US-20140045862-A1 | Cycloalkane Derivatives | TRPV1, TRPA1, SCNN1A | SCN9A 64/4885MEN1 3769/4885KMT2A 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.